Skip to Content

AbobotulinumtoxinA Pregnancy and Breastfeeding Warnings

AbobotulinumtoxinA is also known as: Dysport

AbobotulinumtoxinA Pregnancy Warnings

In animal studies that included rats and rabbits, this drug produced embryo-fetal toxicity at doses lower than or similar to the maximum recommended human dose. There are no controlled data in human pregnancy. US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

This drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus US FDA pregnancy category: Not assigned Risk Summary: There are no human data to establish the presence or absence of drug-associated risk in pregnant women.

See references

AbobotulinumtoxinA Breastfeeding Warnings

Benefit should outweigh risk Excreted into human milk: Unknown Excreted into animal milk: Data not available

No data exist on the medical use of this drug during breastfeeding, although medical use is not expected to produce measurable blood levels and therefore it would not be expected to be available for secretion into breast milk. There is a report of a mother who contracted botulism and successfully breastfed her infant. On admission to the hospital, type A botulinum toxin was detected in her blood and stools; none was detected in the infant's stools. The mother was treated with 2 vials of trivalent botulism antitoxin (IV and IM). A milk sample obtained 4 hours after administration of the antitoxin had no detectable botulinum toxin or botulism organisms.

See references

References for pregnancy information

  1. "Product Information. Dysport (abobotulinumtoxinA)." Tercica Inc, Brisbane, CA.

References for breastfeeding information

  1. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):
  2. "Product Information. Dysport (abobotulinumtoxinA)." Tercica Inc, Brisbane, CA.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.